Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Deponit BE/BA Submissions Supported By FDA Guidances - Schwarz Pharma

Executive Summary

Recent FDA guidances on bioequivalence support Schwarz Pharma's argument that it has submitted adequate BE and bioavailability data for its transdermal nitroglycerin product Deponit under the Drug Efficacy Study Implementation program, Schwarz argued in recent correspondence to FDA.

You may also be interested in...



Individual BE Replicate Study Design To Be Analyzed Over Two Years By FDA

FDA is planning to conduct a two-year evaluation of its recommended replicate design method to determine whether a transition away from average bioequivalence criterion and towards individual and population BE criteria should occur.

FDA Should Designate New Nitroglycerin Reference Product, Firms Say

FDA should choose a new reference product for nitroglycerin, manufacturers suggested in letters to FDA requesting hearings on the proposed withdrawal of ANDAs for nitroglycerin products.

DESI withdrawals

FDA is providing opportunities for hearings on its proposals to withdraw approval of 25 ANDAs for certain single-entity coronary vasodilator products containing isosorbide dinitrate, and for one NDA and five ANDAs for certain nitroglycerin transdermal systems. The agency is proposing to withdraw approval for the products because the sponsors failed to submit bioequivalency/bioavailability data required under the Drug Efficacy Study Implementation program. Several of the products listed in the March 22 and March 25 Federal Register notices are no longer being marketed, sponsors indicated

Related Content

UsernamePublicRestriction

Register

PS035033

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel